News
MBCOF
0.120
NaN%
--
Marvel Biosciences launches up to C$3M private placement
Seeking Alpha · 07/16 20:04
Marvel Biosciences Announces Private Placement for up to $3.0 Million
Newsfile · 07/16 20:00
Marvel Biosciences backs European Purine Meeting with autism research presentation on A2A receptors
PUBT · 06/26 11:00
New Autism Research to be Presented at European Purine Scientific Meeting
Barchart · 06/26 06:00
Marvel Biosciences awards 50,001 deferred share units to independent directors
PUBT · 05/20 11:11
Marvel Biosciences Announces Grant of Deferred Share Units
Newsfile · 05/20 11:00
Marvel Biosciences to present at Neuroscience Innovation Partnering and Licensing Summit
PUBT · 04/23 11:31
Marvel Biosciences closes $500,000 convertible debenture offering
PUBT · 04/17 20:47
Marvel Biosciences Announces Closing of Convertible Debenture Offering
Newsfile · 04/17 20:30
Marvel Biosciences identifies two pediatric liquid MB-204 formulations with up to 91% bioavailability
PUBT · 04/16 11:04
Marvel Biosciences lowers conversion price for proposed debenture offering
Seeking Alpha · 04/13 21:38
Marvel Biosciences cuts debenture conversion price to $0.17 per share
PUBT · 04/13 21:31
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
Newsfile · 04/13 21:31
Marvel Biosciences plans private placement of up to $500,000 convertible debentures
Reuters · 04/08 20:42
Marvel Biosciences Announces Proposed Convertible Debenture Offering
Newsfile · 04/08 20:30
Marvel Biosciences partners with 5 Horizons Ventures to fund MB-204 Phase I trial
Reuters · 04/07 16:26
MARVEL BIOSCIENCES CORP - 5 HORIZONS VENTURES TO FUND 15% OF CRO COSTS FOR PHASE I MB-204 TRIAL
Reuters · 04/07 11:30
Marvel Biosciences secures CAD 0.6 million Alberta Innovates funding for MB-204 Phase I trial
Reuters · 03/30 11:32
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
Barchart · 03/30 06:30
Marvel Biosciences selects Novotech as CRO; Phase I trial of MB-204 moves toward human testing
Reuters · 03/25 11:30
More
Webull provides a variety of real-time MBCOF stock news. You can receive the latest news about Marvel Biosciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About MBCOF
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.